M Hittinger1, S Barthold2, A Gress3, B Wiegand1, L Siebenbürger1, C Börger1, M Berger4, T Krebs4, CM Lehr1, 2, 5, H Groß1
1PharmBioTec GmbH, Saarbrücken, Germany
2Saarland University, Department of Pharmacy, Saarbrücken, Germany
3Max Planck Institute for Informatics, Saarbrücken, Germany
4Vitrocell Systems GmbH, Waldkirch, Germany
5Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), HZI, Saarbrücken, Germany
This poster shows a newly developed instrument which can be used with commercial dry powder inhaler devices and offers flexible adjustment of the flow rate and other process parameters. Salbutamol sulfate dry powder formulation and sodium fluorescein were investigated in the device. The Results were estimated by electron microscop and the deposition of salbutamol sulfate was quantified by HPLC-MS analysis.
In order to replace animal testing in pulmonary drug delivery, the Pharmaceutical Aerosol Deposition Device on Cell Culture (PADDOCC), was originally designed by Hein et al. (Hein et al., 2010, 2011) to enable deposition of dry powder formulations from commercial metered dose in halers (DPI’s) on pulmonary cell cultures under physiological conditions. However, this prototype was still limited in several aspects which necessitated a complete redesign of such platform for aerosol testing. The newly developed instrument can be used with commercial dry powder inhaler devices and offers flexible adjustment of the flow rate and other process parameters. We investigated different dry powders and their performance in the system.